Lilly Poised for GLP-1 Dominance: TD Cowen Forecasts 62% Share of $150B Market by 2030
Summary
TD Cowen has significantly raised its 2030 global GLP-1 market forecast to $150 billion, projecting Eli Lilly will capture a dominant 62% share. This implies a massive future revenue stream for Lilly, estimated at around $93 billion annually from GLP-1 drugs by 2030. A portfolio manager also favors Lilly's strong cash flows, which are being used to fund pipeline investments in oncology and mental health. This news reinforces the company's strong position following recent FDA approvals for Foundayo, robust Q1 2026 results, and strategic manufacturing investments.
At the time of this announcement, LLY was trading at $1,123.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,166.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.